SCHEMBL15035910

SCHEMBL15035910

CCOc1cc2cnc(Nc3ccc(NC4CCN(C)CC4)cc3)nc2n(Cc2scnc2S(=O)(=O)c2ccncc2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 3/20 0.38
PKN1 Q16512 3/20 0.38
PAK3 O75914 2/20 0.38
PAK2 Q13177 2/20 0.38
TNK2 Q07912 1/20 0.38
ALK Q9UM73 2/20 0.37
FGFR1 P11362 4/20 0.37
CDK4 P11802 3/20 0.37
CCND1 P24385 3/20 0.37
FGFR2 P21802 1/20 0.37
FGFR4 P22455 1/20 0.37
FGFR3 P22607 1/20 0.37
JAK3 P52333 1/20 0.36
EGFR P00533 1/20 0.36
CCND2 P30279 2/20 0.36
CCND3 P30281 2/20 0.36
WEE1 P30291 1/20 0.36
PAK4 O96013 2/20 0.36
PDGFRB P09619 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034945 0.81 TNK2 (0.39) PAK1PKN1PAK3PAK2TNK2
SCHEMBL15035807 0.81 PAK4 (0.42) PKN1TNK2ALKJAK3WEE1
SCHEMBL15035751 0.79 RIPK2 (0.37) FGFR1CDK4CCND1FGFR2FGFR4
SCHEMBL15035678 0.79 BRAF (0.35) FGFR1CDK4CCND1FGFR2FGFR4
SCHEMBL15035700 0.78 WEE1 (0.41) TNK2FGFR1CDK4CCND1FGFR2
SCHEMBL15034837 0.78 CDK4 (0.41) PAK1PKN1TNK2FGFR1CDK4
SCHEMBL15035052 0.76 TNK2 (0.41) PAK1PKN1TNK2ALKFGFR1
SCHEMBL15035761 0.74 JAK2 (0.40) PKN1TNK2FGFR1CDK4CCND1
SCHEMBL15034814 0.73 PAK4 (0.46) PKN1TNK2FGFR1CDK4CCND1
SCHEMBL15034978 0.73 PAK4 (0.47) PKN1ALKJAK3EGFRWEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK6 PAK1 6/4885PKN1 430/4885PAK3 2/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 PAK1 4/4885PKN1 326/4885PAK3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.